vs

Side-by-side financial comparison of INFINITY NATURAL RESOURCES, INC. (INR) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.

INFINITY NATURAL RESOURCES, INC. is the larger business by last-quarter revenue ($115.5M vs $66.0M, roughly 1.7× SOLENO THERAPEUTICS INC). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs 17.3%, a 22.1% gap on every dollar of revenue.

SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.

INR vs SLNO — Head-to-Head

Bigger by revenue
INR
INR
1.7× larger
INR
$115.5M
$66.0M
SLNO
Higher net margin
SLNO
SLNO
22.1% more per $
SLNO
39.4%
17.3%
INR

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
INR
INR
SLNO
SLNO
Revenue
$115.5M
$66.0M
Net Profit
$20.0M
$26.0M
Gross Margin
98.3%
Operating Margin
47.0%
33.5%
Net Margin
17.3%
39.4%
Revenue YoY
Net Profit YoY
134.0%
EPS (diluted)
$1.33
$0.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INR
INR
SLNO
SLNO
Q4 25
$115.5M
Q3 25
$78.3M
$66.0M
Q2 25
$72.5M
$32.7M
Q1 25
$84.2M
Net Profit
INR
INR
SLNO
SLNO
Q4 25
$20.0M
Q3 25
$10.4M
$26.0M
Q2 25
$18.0M
$-4.7M
Q1 25
$-34.6M
Gross Margin
INR
INR
SLNO
SLNO
Q4 25
Q3 25
98.3%
Q2 25
97.9%
Q1 25
Operating Margin
INR
INR
SLNO
SLNO
Q4 25
47.0%
Q3 25
30.5%
33.5%
Q2 25
29.9%
-20.0%
Q1 25
-104.5%
Net Margin
INR
INR
SLNO
SLNO
Q4 25
17.3%
Q3 25
13.3%
39.4%
Q2 25
24.8%
-14.4%
Q1 25
-41.1%
EPS (diluted)
INR
INR
SLNO
SLNO
Q4 25
$1.33
Q3 25
$0.65
$0.47
Q2 25
$1.18
$-0.09
Q1 25
$-2.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INR
INR
SLNO
SLNO
Cash + ST InvestmentsLiquidity on hand
$2.8M
$498.9M
Total DebtLower is stronger
$55.0K
Stockholders' EquityBook value
$307.1M
$494.8M
Total Assets
$1.2B
$599.9M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INR
INR
SLNO
SLNO
Q4 25
$2.8M
Q3 25
$4.6M
$498.9M
Q2 25
$6.3M
$286.8M
Q1 25
$4.9M
Total Debt
INR
INR
SLNO
SLNO
Q4 25
$55.0K
Q3 25
Q2 25
Q1 25
$123.0K
Stockholders' Equity
INR
INR
SLNO
SLNO
Q4 25
$307.1M
Q3 25
$288.6M
$494.8M
Q2 25
$10.1M
$240.1M
Q1 25
$-52.2M
Total Assets
INR
INR
SLNO
SLNO
Q4 25
$1.2B
Q3 25
$1.1B
$599.9M
Q2 25
$1.0B
$332.3M
Q1 25
$953.9M
Debt / Equity
INR
INR
SLNO
SLNO
Q4 25
0.00×
Q3 25
Q2 25
Q1 25

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INR
INR
SLNO
SLNO
Operating Cash FlowLast quarter
$75.1M
$43.5M
Free Cash FlowOCF − Capex
$43.5M
FCF MarginFCF / Revenue
65.8%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
3.75×
1.67×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INR
INR
SLNO
SLNO
Q4 25
$75.1M
Q3 25
$42.1M
$43.5M
Q2 25
$70.4M
$-12.6M
Q1 25
$74.2M
Free Cash Flow
INR
INR
SLNO
SLNO
Q4 25
Q3 25
$43.5M
Q2 25
$-12.6M
Q1 25
FCF Margin
INR
INR
SLNO
SLNO
Q4 25
Q3 25
65.8%
Q2 25
-38.6%
Q1 25
Capex Intensity
INR
INR
SLNO
SLNO
Q4 25
Q3 25
0.0%
Q2 25
0.0%
Q1 25
Cash Conversion
INR
INR
SLNO
SLNO
Q4 25
3.75×
Q3 25
4.04×
1.67×
Q2 25
3.91×
Q1 25

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

INR
INR

Oil Reserves$54.0M47%
Natural Gas Reserves$46.8M41%
Natural Gas Liquids Reserves$14.7M13%

SLNO
SLNO

Segment breakdown not available.

Related Comparisons